Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F. Gentile M, et al. Among authors: antonioli e. Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513. Haematologica. 2021. PMID: 32107338 Free PMC article. No abstract available.
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM; Myeloproliferative Disorders Research Consortium (MPD-RC). Antonioli E, et al. Haematologica. 2008 Jan;93(1):41-8. doi: 10.3324/haematol.11653. Haematologica. 2008. PMID: 18166784 Free article.
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni Bezzi C, Scalese M, Dozza L, Marzocchi G, Martello M, Barilà G, Antonioli E, Staderini M, Buda G, Petrini M, Cea M, Quaresima M, Furlan A, Bonalumi A, Cavo M, Zamagni E. Rocchi S, et al. Among authors: antonioli e. Hematol Oncol. 2021 Feb;39(1):41-50. doi: 10.1002/hon.2820. Epub 2020 Nov 1. Hematol Oncol. 2021. PMID: 33085797 Clinical Trial.
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Rizzello I, Cavo M, Dozza L, Rivolti E, Petrucci MT, De Stefano V, Antonioli E, Tosi P, D'Agostino M, Morè S, Gozzetti A, Cea M, Barbato S, Tacchetti P, Pantani L, Mancuso K, Rocchi S, De Cicco G, Fusco A, Zamagni E. Rizzello I, et al. Among authors: antonioli e. Leuk Lymphoma. 2021 Aug;62(8):1897-1906. doi: 10.1080/10428194.2021.1897805. Epub 2021 Mar 18. Leuk Lymphoma. 2021. PMID: 33733993
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Larocca A, Bonello F, Gaidano G, D'Agostino M, Offidani M, Cascavilla N, Capra A, Benevolo G, Tosi P, Galli M, Marasca R, Giuliani N, Bernardini A, Antonioli E, Rota-Scalabrini D, Cellini C, Pompa A, Monaco F, Patriarca F, Caravita di Toritto T, Corradini P, Tacchetti P, Boccadoro M, Bringhen S. Larocca A, et al. Among authors: antonioli e. Blood. 2021 Jun 3;137(22):3027-3036. doi: 10.1182/blood.2020009507. Blood. 2021. PMID: 33739404 Free article. Clinical Trial.
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study.
Del Giudice ML, Gozzetti A, Antonioli E, Orciuolo E, Ghio F, Ciofini S, Candi V, Fontanelli G, Attucci I, Formica G, Bocchia M, Galimberti S, Petrini M, Buda G. Del Giudice ML, et al. Among authors: antonioli e. Medicina (Kaunas). 2021 Aug 28;57(9):900. doi: 10.3390/medicina57090900. Medicina (Kaunas). 2021. PMID: 34577823 Free PMC article.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M. Bruzzese A, et al. Among authors: antonioli e. Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. Hematol Oncol. 2022. PMID: 35608183 Free article.
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.
Efficace F, Gaidano G, Petrucci MT, Niscola P, Cottone F, Codeluppi K, Antonioli E, Tafuri A, Larocca A, Potenza L, Fozza C, Pastore D, Rigolin GM, Offidani M, Romano A, Kyriakou C, Cascavilla N, Gozzetti A, Derudas D, Vignetti M, Cavo M. Efficace F, et al. Among authors: antonioli e. Lancet Healthy Longev. 2022 Sep;3(9):e628-e635. doi: 10.1016/S2666-7568(22)00172-6. Lancet Healthy Longev. 2022. PMID: 36102777 Free article.
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.
Mancuso K, Mina R, Rocchi S, Antonioli E, Petrucci MT, Fazio F, Gozzetti A, Salvini M, Cartia CS, Bertuglia G, Patriarca F, Dalla Palma AB, Barbato S, De Cicco G, Bigi F, Favero E, Tacchetti P, Pantani L, Rizzello I, Puppi M, Talarico M, Solli V, Kanapari A, Cavo M, Zamagni E. Mancuso K, et al. Among authors: antonioli e. Cancer Med. 2024 Nov;13(22):e70266. doi: 10.1002/cam4.70266. Cancer Med. 2024. PMID: 39587728 Free PMC article.
121 results